[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Updates 2025 EPS Guidance with $823M IPR&D Expense",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the 7 most undervalued pot stocks to buy according to analysts. On July 3, the company provided an update to its 2025 earnings guidance to account for a pre-tax acquired in-process research and development (IPR&D) and milestones expense of $823 million in the second quarter of 2025. This expense […]",
    "url": "https://finnhub.io/api/news?id=9ab7b26d3a7b35cbedc41b059d35108a3b002c46aec19867d064291f4355564f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752507054,
      "headline": "AbbVie (ABBV) Updates 2025 EPS Guidance with $823M IPR&D Expense",
      "id": 135935458,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the 7 most undervalued pot stocks to buy according to analysts. On July 3, the company provided an update to its 2025 earnings guidance to account for a pre-tax acquired in-process research and development (IPR&D) and milestones expense of $823 million in the second quarter of 2025. This expense […]",
      "url": "https://finnhub.io/api/news?id=9ab7b26d3a7b35cbedc41b059d35108a3b002c46aec19867d064291f4355564f"
    }
  },
  {
    "ts": null,
    "headline": "AnaptysBio: Potential Promise, But Some Cause For Skepticism",
    "summary": "AnaptysBioâs lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find out why ANAB stock is a hold.",
    "url": "https://finnhub.io/api/news?id=a8f2a499ca9319c5d73cf6d5524bcd8a35a420e9b32cb33fb26f779c2f4e0f05",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752490011,
      "headline": "AnaptysBio: Potential Promise, But Some Cause For Skepticism",
      "id": 135926879,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192786673/image_2192786673.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AnaptysBioâs lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find out why ANAB stock is a hold.",
      "url": "https://finnhub.io/api/news?id=a8f2a499ca9319c5d73cf6d5524bcd8a35a420e9b32cb33fb26f779c2f4e0f05"
    }
  }
]